The genetic polymorphisms at the 16th (Arg--> Gly) and 27th (Gln-->Glu) amino acid positions of the beta2-adrenergic receptor (ADRB2) may be linked to various asthma-related phenotypes. These include the adverse effects on lung function known to occur following the regular use of albuterol. The study aimed to determine the association between these two ADRB2 SNPs, their haplotypes and the phenotypes in Thai asthmatic patients. One-hundred and thirty asthmatic patients were genotyped at the Arg16Gly and Gln27Glu polymorphisms. Demographic data, disease severities, pulmonary function tests and medication usages were recorded for each patient. The frequencies of the Arg16 and Gln27 alleles were found to be 56.9% and 91.2%, respectively, while the linkage disequilibrium coefficient between the two SNPs was 0.36. Three haplotypes were estimated, i.e., Arg-Gln, Gly-Gln and Gly-Glu with frequencies of 148 (56.9%), 89 (34.2%) and 23 (8.9%), respectively. The mean percentages for predicted FEV1 (%FEV1) for these corresponding haplotypes were 73.5 (SD = 16.3), 72.4 (SD = 17.4) and 80.7 (SD = 13.1), respectively (p = 0.258). Additionally, the number of hospitalizations, emergency visits and inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) usages were lower in Gln/Glu subjects than for Gln/Gln genotyped patients, with values of 0% versus 11.9% (p = 0.122) for hospitalizations; 4.5% versus 18.8% (p = 0.121) for emergency visits; and 50% versus 76.6%, (p = 0.042) for ICS/LABA usages. The presence of the Glu27 allele in Thai asthmatic patients is associated with a decreased asthma severity, higher %FEV1 values, less frequent hospitalizations and emergency visits, and decreased ICS/LABA usage.
Download full-text PDF |
Source |
---|
PLoS One
January 2025
Asthma and Air Quality Branch, Division of Environmental Health Science and Practice, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
The epidemiology of allergic bronchopulmonary aspergillosis (ABPA) in the United States is not well-described. To estimate national ABPA prevalence among patients with asthma or cystic fibrosis, characterize ABPA testing practices, and describe ABPA clinical features, treatment, and 6-month outcomes. We used the 2016-2022 Merative™ MarketScan® Commercial/Medicare and Multi-State Medicaid Databases to identify cohorts of patients with 1) asthma, 2) cystic fibrosis (CF), and 3) ABPA.
View Article and Find Full Text PDFJ Eval Clin Pract
February 2025
Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, University of Jordan, Amman, Jordan.
Background: Chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) may deteriorate into acute exacerbations requiring hospitalization. Assessing the predictors of prolonged hospital stays could help identify potential interventions to reduce the burden on patients and healthcare systems.
Aim: This study aimed to identify the risk factors attributed to prolonged hospital stays among patients admitted with acute exacerbations of chronic respiratory disorders in Jordan.
Indian J Pediatr
January 2025
Department of Pediatrics, Regency Hospital, Kanpur, Uttar Pradesh, India.
Inflamm Res
January 2025
Institute of Allergy and Clinical Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea.
Particulate matter (PM) exposure has been proposed as one of the causes of steroid resistance. However, studies investigating this using patient samples or animals are still lacking. Therefore, in this study, we aimed to investigate the changes in cytokines and mTOR (mammalian target of rapamycin) activation in patients with steroid resistant asthma and the role of mTOR in a mouse model of steroid resistant asthma induced by PM.
View Article and Find Full Text PDFJ Asthma
January 2025
Department of Biomedical Science, Humanitas University, Pieve Emanuele (Milano), Italy.
Exacerbations and suboptimal disease control are common in severe asthma with an eosinophilic phenotype (SAep). Mepolizumab, an anti-interleukin-5 monoclonal antibody, has demonstrated efficacy and safety in randomized controlled trials (RCTs). We aimed to strengthen the real-world evidence base for mepolizumab in SAep.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!